期刊
FRONTIERS IN IMMUNOLOGY
卷 12, 期 -, 页码 -出版社
FRONTIERS MEDIA SA
DOI: 10.3389/fimmu.2021.714822
关键词
cancer immunotherapy; cellular reprogramming; tumor immunology; CAR-T; transcription factor; dendritic cell; antigen presentation; cancer vaccine
类别
资金
- Cancerfonden [20 0939]
- Swedish research council [2020-00615]
- European Research Council [866448-TrojanDC]
- Novo Nordisk Foundation [0056527]
- FCT [PTDC/MED-IMU/4520/2020]
- Knut and Alice Wallenberg foundation
- Medical Faculty at Lund University
- Region Skane
- Cancerfonden postdoctoral fellowship [190008]
- FCT doctoral fellowships [PD/BD/146424/2019, SFRH/BD/133233/2017]
- Swedish Research Council [2020-00615] Funding Source: Swedish Research Council
- Fundação para a Ciência e a Tecnologia [PTDC/MED-IMU/4520/2020] Funding Source: FCT
The development of cancer immunotherapy is based on advances in understanding the interaction between cancer cells and the immune system, with cell fate reprogramming providing new alternatives for personalized immunotherapy. Technologies such as induced pluripotent stem cells (iPSCs) enable the study and generation of clinically useful immune cells, offering potential for enhancing anti-tumor properties and addressing challenges in cellular immunotherapy. Advances in in vivo reprogramming and gene delivery mechanisms are opening exciting avenues for direct manipulation of immune or tumor cells in situ, providing new tools for overcoming obstacles in cancer immunotherapy.
Advances in understanding how cancer cells interact with the immune system allowed the development of immunotherapeutic strategies, harnessing patients' immune system to fight cancer. Dendritic cell-based vaccines are being explored to reactivate anti-tumor adaptive immunity. Immune checkpoint inhibitors and chimeric antigen receptor T-cells (CAR T) were however the main approaches that catapulted the therapeutic success of immunotherapy. Despite their success across a broad range of human cancers, many challenges remain for basic understanding and clinical progress as only a minority of patients benefit from immunotherapy. In addition, cellular immunotherapies face important limitations imposed by the availability and quality of immune cells isolated from donors. Cell fate reprogramming is offering interesting alternatives to meet these challenges. Induced pluripotent stem cell (iPSC) technology not only enables studying immune cell specification but also serves as a platform for the differentiation of a myriad of clinically useful immune cells including T-cells, NK cells, or monocytes at scale. Moreover, the utilization of iPSCs allows introduction of genetic modifications and generation of T/NK cells with enhanced anti-tumor properties. Immune cells, such as macrophages and dendritic cells, can also be generated by direct cellular reprogramming employing lineage-specific master regulators bypassing the pluripotent stage. Thus, the cellular reprogramming toolbox is now providing the means to address the potential of patient-tailored immune cell types for cancer immunotherapy. In parallel, development of viral vectors for gene delivery has opened the door for in vivo reprogramming in regenerative medicine, an elegant strategy circumventing the current limitations of in vitro cell manipulation. An analogous paradigm has been recently developed in cancer immunotherapy by the generation of CAR T-cells in vivo. These new ideas on endogenous reprogramming, cross-fertilized from the fields of regenerative medicine and gene therapy, are opening exciting avenues for direct modulation of immune or tumor cells in situ, widening our strategies to remove cancer immunotherapy roadblocks. Here, we review current strategies for cancer immunotherapy, summarize technologies for generation of immune cells by cell fate reprogramming as well as highlight the future potential of inducing these unique cell identities in vivo, providing new and exciting tools for the fast-paced field of cancer immunotherapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据